# Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/pharmacokinetic-based-criteria-for-supporting-alternative-dosing-regimens-of-programmed-cell-death-receptor-1-pd-1-or-programmed-cell-death-ligand-1-pd-l1-blocking-antibodies-for-treatment-of-patients-with-cancer-guidance-for-industry/39b5200a-95fe-45d2-ac1a-170502282ac4

> FDA guidance document: Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry. Issue date: December 06, 2022. Get complete insights and analysis.

---

## Details

- Title: Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2022-12-06
- Last Changed: 2022-12-06
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0691">FDA-2021-D-0691</a>

## Related Documents

- [Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/bladder-cancer-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/b3fd959c-72c5-4e86-a4a9-5fa31d0ce7b7)
- [Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/db30c852-ed7b-4054-8906-3aadd3851179)
- [Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical](https://www.keypedia.com/guidances/guidance-document/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-for-industry-clinicalmedical/3000f20b-5abd-4861-8188-ffcc1d35913d)